Title |
Febuxostat for treating chronic gout
|
---|---|
Published in |
Cochrane database of systematic reviews, November 2012
|
DOI | 10.1002/14651858.cd008653.pub2 |
Pubmed ID | |
Authors |
Jean H Tayar, Maria Angeles Lopez‐Olivo, Maria E Suarez‐Almazor |
Abstract |
Gout is the most common inflammatory arthritis in men over 40 years and has an increasing prevalence among postmenopausal women. Lowering serum uric acid levels remains one of the primary goals in the treatment of chronic gout. In clinical trials, febuxostat has been shown to be effective in lowering serum uric acid levels to < 6.0 mg/dL. |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | 18% |
Mexico | 1 | 9% |
Colombia | 1 | 9% |
Germany | 1 | 9% |
Japan | 1 | 9% |
Unknown | 5 | 45% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 10 | 91% |
Practitioners (doctors, other healthcare professionals) | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 168 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 2 | 1% |
United Kingdom | 1 | <1% |
Italy | 1 | <1% |
Denmark | 1 | <1% |
Unknown | 163 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 30 | 18% |
Student > Bachelor | 28 | 17% |
Researcher | 18 | 11% |
Student > Ph. D. Student | 15 | 9% |
Student > Postgraduate | 10 | 6% |
Other | 15 | 9% |
Unknown | 52 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 58 | 35% |
Nursing and Health Professions | 11 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 9 | 5% |
Social Sciences | 7 | 4% |
Psychology | 6 | 4% |
Other | 17 | 10% |
Unknown | 60 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 February 2020.
All research outputs
#2,266,417
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#4,664
of 11,499 outputs
Outputs of similar age
#15,226
of 192,725 outputs
Outputs of similar age from Cochrane database of systematic reviews
#93
of 238 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,725 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 238 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.